mPRα Inhibitors

mPRα inhibitors constitute a class of compounds designed to selectively modulate the activity of membrane progesterone receptor alpha (mPRα). Among these inhibitors, PHTPP and G-15 stand out as direct antagonists, specifically targeting mPRα and preventing its activation. These compounds exert their effects by interfering with the ligand-binding site of mPRα, thereby inhibiting downstream signaling events. In addition to direct inhibitors, several compounds indirectly modulate mPRα activity by targeting related signaling pathways. Mifepristone, a well-known anti-progestin, influences mPRα through its actions on progesterone receptors, disrupting the downstream effects of mPRα activation. Progesterone Receptor Antagonist II, UPA (Ulipristal Acetate), and GSK4716 also fall into this category, exerting their effects on progesterone receptors and GPER, impacting the interconnected signaling pathways associated with mPRα.

Tamoxifen and ICI 182,780 (Fulvestrant), both selective estrogen receptor modulators, indirectly influence mPRα activity by modulating estrogen receptor-mediated signaling. G15, AG-205, CGP 42112, and G-36, all targeting GPER and GPR30, contribute to the modulation of mPRα activity through shared downstream pathways. This diverse class of mPRα inhibitors offers researchers a comprehensive toolkit for investigating the role of mPRα in cellular processes, including its involvement in reproductive biology and potential implications in various pathophysiological conditions. The precise control afforded by these inhibitors enables a deeper understanding of mPRα function within the intricate network of steroid hormone signaling.